AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 JAN 23 - (NewsRx.com & NewsRx.net) -- by Sonia Nichols, senior medical writer - Tumor immunity can be generated with heat shock protein (HSP) gene therapy, but researchers caution that simultaneous administration with other immunostimulatory gene therapies may have reduced or even unintended effects.
Their warning, resulting from a study of gene therapies administered to murine models, demonstrates why it will be some time before gene therapies are routinely prescribed for humans.
HSPs have been hailed for their role in stimulating antitumor immunity, according to researchers at New Zealand's University of Auckland. "HSPs facilitate signal 1 in the two-signal model of T-cell costimulation, whereas cell adhesion molecules such as B7.1 provide secondary (signal 2) costimulatory signals," M. Rafiee and associates noted in Cancer Gene Therapy.
In previous experiments performed by Rafiee and team, murine vaccination with HSP derived from EL-4 lymphoma elicited a weak antitumor response. Their current study assessed the efficacy of rodent HSP70.1 injected directly into murine tumors, and it also evaluated the effects of simultaneously administering immunostimulatory gene therapy.
HSP70.1 gene therapy completely destroyed murine tumors and also stimulated a strong immune response against tumor cells that was mediated by both CD4[superscript]+ and CD8[superscript]+ T cells ...
Source: HighBeam Research, Heat Shock Protein Gene Transfer Creates Systemic Response In...